Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation

Abstract

Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions, and the use of compositions containing platelet-rich plasma to accelerate or complete the differentiation of a cell line. Particularly, use of platelet-rich plasma in conjunction with cell differentiation.

What is claimed is: 
     
         1 . A method of producing induced pluripotent stem (iPS) cells comprising:
 obtaining fibroblast cells from skin tissue from an individual,   administering a growth factor selected from the group consisting of vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), plerixafor, sargramostim, γ-tocotrienol, vitamin E, ancestim and bone morphogenic growth factor to the individual,   isolating platelet-rich plasma (PRP) from whole blood of the individual, and   treating the fibroblast cells of the individual with the isolated PRP.   
     
     
         2 . The method of  claim 1 , wherein the whole blood is obtained from spleen or bone marrow. 
     
     
         3 . The method of  claim 1 , wherein the platelet-rich plasma comprises a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher, and further comprising treating the fibroblast cells of the individual with a bone marrow concentrate and fraction of adipose tissue. 
     
     
         4 . The method of  claim 1 , wherein the platelet-rich plasma comprises a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher, and further comprising CD34+ cells at a concentration 1-3×10 9  per liter to 100×10 9  per liter or higher. 
     
     
         5 . The method of  claim 1 , wherein the platelet-rich plasma comprises a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher, and further comprising stromal-derived factor −1 (SDF-1) in a concentration of 100 pg/ml to 5000 pg/ml. 
     
     
         6 . The method of  claim 1 , further comprising measuring the potency of platelet rich plasma by visually observing it over time by at least one method selected from the group consisting of cellular movement, microfluidics, and chemotaxis. 
     
     
         7 . The method of  claim 1 , wherein the PRP is used in drug discovery to identify new targets. 
     
     
         8 . The method of  claim 1 , wherein the PRP is used for nuclear reprogramming, cell proliferation, or differentiation. 
     
     
         9 . The method of  claim 1 , further comprising administrating granulocyte colony-stimulating factor (G-CSF) or any other molecule that stimulates the production of stem cells by the body prior to the preparation of platelet-rich plasma from any source. 
     
     
         10 . A composition comprising:
 cells from an individual, and   platelet-rich plasma (PRP) isolated from whole blood of the individual, wherein the cells of the individual are treated with the PRP to produce induced pluripotent stem (iPS) cells.   
     
     
         11 . The composition of  claim 10 , wherein the cells are fibroblast cells from skin tissue from the individual. 
     
     
         12 . The composition of  claim 10 , further comprising a growth factor selected from the group consisting of vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), plerixafor, sargramostim, γ-tocotrienol, vitamin E, ancestim and bone morphogenic growth factor to the individual. 
     
     
         13 . The composition of  claim 10 , wherein the whole blood is obtained from spleen or bone marrow. 
     
     
         14 . The composition of  claim 10 , wherein the composition comprises the platelet-rich plasma comprising a platelets concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises at least one cell selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, adult stem cells, and progenitor cell lines. 
     
     
         15 . The composition of  claim 14 , wherein the adult stem cells comprise mesenchymal stem cells. 
     
     
         16 . The composition of  claim 10 , wherein the composition comprises the platelet-rich plasma comprising a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises progenitor or precursor stem cell lines. 
     
     
         17 . The composition of  claim 16 , wherein the progenitor or precursor stem cell lines comprise mesenchymal stem precursor lines. 
     
     
         18 . The composition of  claim 10 , wherein the composition comprises the platelet-rich plasma comprising a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises CD34+ cells at a concentration 1-3×10 9  per liter to 100×10 9  per liter or higher. 
     
     
         19 . The composition of  claim 15 , wherein the composition comprises the platelet-rich plasma comprising a platelets in a concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises stromal-derived factor −1 (SDF-1) in a concentration of 100 pg/ml to 5000 pg/ml. 
     
     
         20 . The composition of platelet rich plasma comprising the platelet rich plasma derived from induced pluripotent stem cells at a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher and pluripotent stem cells in any concentration or form.